• 1
    Calderon M, Mösges R, Hellmich M, Demoly P. Towards evidence-based medicine in specific grass pollen immunotherapy. Allergy 2010;65:420434.
  • 2
    Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brien F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468475.
  • 3
    Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003; Art. No.: CD002893. DOI: 10.1002/14651858. CD002893.
  • 4
    Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005;60:412.
  • 5
    Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010; Art. No.: CD002893. DOI: 10.1002/14651858.CD002893.pub2
  • 6
    ClarkeM, OxmanA, eds. Cochrane Reviewers’ Handbook 4.2.0 [updated March 2003]. The Cochrane Library [Issue 2]. Oxford: Update Software.
  • 7
    Moher D, Ba’ Pham, Jones A, Cook DJ, Jadad AR, Moher M et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609613.
  • 8
    HigginsJPT, GreenS, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from
  • 9
    The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
  • 10
    Amar SM, Harbeck RJ, Sills M, Silveira LJ, O’Brien H, Nelson HS. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in multiallergen extract. J Allergy Clin Immunol 2009;124:150156.
  • 11
    Andre C, Perrin-Fayolle M, Grosclaude M, Couturier P, Basset D, Cornillon J et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with standardized ragweed extract in patients with seasonal rhinitis. Int Arch Allergy Immunol 2003;131:111118.
  • 12
    Ariano R, Spadolini I, Panzani RC. Efficacy of sublingual immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study. Allergol Immunopathol 2001;29:238244.
  • 13
    Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double blind, placebo-controlled study. Pediatr Pulmonol 2001;32:4955. Published and unpublished data.
  • 14
    Bowen T, Greenbaum J, Charbonneu Y, Hebert J, Filderman R, Sussman G et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjuctivitis. Ann Allergy Asthma Immunol 2004;93:425430. Published and unpublished data.
  • 15
    Bufe A, Ziegler-Kirbach E, Stoeckman E, Heidemann P, Gehlhar K, Holland-Letz T et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms, a double-blind, placebo-controlled study. Allergy 2004;59:498504. Published and unpublished data.
  • 16
    Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167173.e7.Published data only (unpublished sought but not used)
  • 17
    Caffarelli C, Sensi LG, Marcucci F, Cavagni G. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000;55:11421147. Published and unpublished data.
  • 18
    Calderón M, Essendrop M. Specific immunotherapy with high dose SQ standardized grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol 2006;16:338344.
  • 19
    Cao LF, Lu Q, Gu HL, Chen YP, Zhang Y, Lu M et al. Clinical evaluation for sublingual immunotherapy of allergic asthma and atopic rhinitis with Dermatophagoides Farinae Drops. Zhonghua Er Ke Za Zhi 2007;45:736741. Published and unpublished data.
  • 20
    Casanovas M, Guerra F, Moreno C, Miguel R, Maranon F, Daza JC. Double-blind, placebo-controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually. J Investig Allergol Clin Immunol 1994;4: 305314. Published and unpublished data.
  • 21
    Clavel R, Bousquet J, Andre C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 1998;53:493498.
  • 22
    Purello-D’Ambrosio F. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardised in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy 1999;54:968973. Published and unpublished data.
  • 23
    Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006;61:185190.
  • 24
    Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S, Emminger W et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434440.
  • 25
    de Blay F, Purohit A, Kanny G, Le Sellin J, Wessel F, Leynadier F et al. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind placebo controlled study [Abstract]. In: XXII Congress of the European Academy of Allergology and Clinical Immunology (EAACI). 2003:780. Published and unpublished data.
  • 26
    Di Rienzo V, Pucci S, D’Alo S, Di Cara G, Incorvaia C, Frati F et al. Effects of high-dose sublingual immunotherapy on quality of life in patients with cypress-induced rhinitis: a placebo-controlled study. Clin Exp Allergy Rev 2006;6:6770. Published and unpublished data.
  • 27
    Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:13381345.
  • 28
    Drachenberg KJ, Pfeiffer P, Urban E. Sublingual immunotherapy – results from a multi-centre, randomised, double-blind, placebo-controlled study with a standardised birch and grass/rye pollen extract. Allergologie 2001;24:525534.
  • 29
    Dubakiene R, Kleinjans HAJ. Effectiveness of specific sublingual IT (SLIT) with tree pollen. A placebo controlled study in 119 patients [Abstract]. In: XXII Congress of European Academy of Allergology and Clinical Immunology. 2003. Published and unpublished data.
  • 30
    Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802809. Published and unpublished data.
  • 31
    Feliziani V, Lattuada G, Parmiani S, Dall’Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergologia et Immunopathologia (Madrid) 1995;23:224230. Published and unpublished data.
  • 32
    Grosclaude M, Bouillot P, Alt R, Leynadier F, Scheimann P, Rufin P et al. Safety of various dosage regimens during induction of sublingual immunotherapy: a preliminary study. Int Arch Allergy Immunol 2002;129:248253.
  • 33
    Guez S, Vatrinet C, Fadel R, Andre C. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000;55:369375. Published and unpublished data.
  • 34
    Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract ( in children. Pediatr Allergy Immunol 1997;8:2127. Published and unpublished data.
  • 35
    Hordijk GJ, Antvelink JB, Luwema RA. Sublingual immunotherapy with a standardised grass pollen extract: a double-blind, placebo-controlled study. Allergologia et Immunopathologia (Madrid) 1998;26:234240.
  • 36
    Ibañez MD, Kaiser F, Knecht R, Armentia A, Schöpfer H, Tholstrup B et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol 2007;18:516522.
  • 37
    Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003;14:216221.
  • 38
    Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59:4553.
  • 39
    Kleine-Tebbe J, Ribel M, Herold DA. Safety of SQ-standardized grass allergen tablet for sublingual immunotherapy: a randomized, placebo controlled trial. Allergy 2006;61:181184.
  • 40
    La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104:425432. Published and unpublished data.
  • 41
    Lima M, Wilson DR, Roberts A, Walker SM, Durham SR. Grass pollen sublingual immunotherapy (SLIT) for seasonal rhinoconjunctivitis: a randomised controlled trial. Clin Exp Allergy 2002;32:507514. Published and unpublished data.
  • 42
    Malling HJ, Lund L, Ipsen H, Poulsen L. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol 2006;16:162168. Published and unpublished data.
  • 43
    Marcucci F, Sensi L, Di Cara G, Salvatori S, Bernini M, Pecora S et al. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. Pediatr Allergy Immunol 2005;16: 519526.
  • 44
    Marcucci F, Sensi L, Frati F, Bernardini R, Novembre E, Barbato A et al. Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites. Allergy 2003;58:657662.
  • 45
    Nelson HS, Oppenheimer J, Vatsia GA, Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993;92:229236.
  • 46
    Ott H, Sieber J, Brehler R, Fölster-Holst R, Kapp A, Klimek L et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009;64:179186.
  • 47
    Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003;33:16411647. Published and unpublished data.
  • 48
    Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos ML, Bruno ME et al. Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitis patients. A double-blind, placebo-controlled study. Allergologia et Immunopathologia (Madrid) 2006;34:194198. Published and unpublished data.
  • 49
    Panzner P, Petrás M, Sýkora T, Lesná I. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually. Respir Med 2008;102:12961304. Published and unpublished data.
  • 50
    Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998;351:629632. Published and unpublished data.
  • 51
    Passalacqua G, Albano M, Riccio A, Fregonese L, Puccinelli P, Parmiani S et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999;104:964968. Published and unpublished data.
  • 52
    Passalacqua G, Pasquali M, Ariano R, Lombardi C, Giardini A, Baiardini I et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 2006;61:849854. Published and unpublished data.
  • 53
    Peter R, Kleinjans H, Hecker H. Significant increase in IgG(4) levels after slit grass treatment. A double-blind, placebo-controlled, multi-center study (twin grasses study). Allergy 2009;90:352353. Published and unpublished data.
  • 54
    Pfaar O, Klimek L. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 2008;100:256263. Published and unpublished data.
  • 55
    Pradalier A, Basset D, Claudel A, Couturier P, Wessel F, Galvain S et al. Sublingual-swallow immunotherapy (SLIT) with a standardised five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999;54:819828.
  • 56
    Rolinck-Werninghaus C, Wolf H, Liebke C, Baars JC, Lange J, Kopp MV. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhino-conjunctivitis to grass pollen. Allergy 2004;59:12851293. Published and unpublished data.
  • 57
    Röder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007;119:892898. Published and unpublished data.
  • 58
    Sabbah A, Hassoun S, Le Sellin J, Andre C, Sicard H. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994;49:309313.
  • 59
    Sanchez Palacios A, Schamann F, Garcia JA. Sublingual immunotherapy with cat extract, personal experience. Allergologia et Immunopathologia (Madrid) 2001;29:6065.
  • 60
    Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high- dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004;114:831837.
  • 61
    Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite: a double-blind study. Allergologia et Immunopathologia (Madrid) 1990;18:277284. Published and unpublished data.
  • 62
    Tari MG, Mancino M, Madonna F, Buzzoni L, Parmiani S. Immunologic evaluation of 24 month course of sublingual immunotherapy. Allergologia at Immunopathologia 1994;22:209216.
  • 63
    Tonnel AB, Scherpereel A, Douay B, Mellin B, Leprince D, Goldstein N et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004;59:491497. Published and unpublished data.
  • 64
    Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. J Investig Allergol Clin Immunol 1995;5:2530. Published and unpublished data.
  • 65
    Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006;61:11771183.
  • 66
    Vervloet D, Birnbaum J, Laurent P, Hugues B, Fardeau MF, Massabie-Bouchat YP et al. Safety and efficacy of Juniperus Ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis: a double-blind, placebo-controlled study. Int Arch Allergy Immunol 2007;142:239246.
  • 67
    Voltolini S, Modena P, Minale P, Bignardi D, Troise C, Puccinelli P et al. Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule. Allergologia et Immunopathologia (Madrid) 2001;29:103110. Published and unpublished data.
  • 68
    Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, Andre C et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53:662672. Published and unpublished data.
  • 69
    Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160166.e3. Published and unpublished data.
  • 70
    Wessner DB, Wessner S, Mohrnschlager M, Rakoski J, Ring J. Efficacy and safety of sublingual immunotherapy in adults with allergic rhinoconjunctivitis: results after 2 years of controlled trial [Abstract]. Allergy 2001;56(Suppl 68):88. Published and unpublished data.
  • 71
    Wutrich B, Bucher C, Jorg W, Bircher A, Eng P, Schneider Y et al. Placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. J Investig Allergol Clin Immunol 2003;13:145148. Published and unpublished data.
  • 72
    Calderon MA. Meta-analyses of specific immunotherapy trials. Drugs Today (Barc) 2008;44(Suppl B):3134.
  • 73
    Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):S8S160.
  • 74
    Dahl R, Kapp A, Colombo G, De Monchy JG, Rak S, Emminger W et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008;121:512518.
  • 75
    Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010;125:131138.e1-7.
  • 76
    Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, Art. No.: CD001936. DOI: 10.1002/14651858.CD001936.pub2.
  • 77
    Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637639.
  • 78
    Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;14:11911194.
  • 79
    Nieto A, Mazon A, Pamies R, Bruno L, Navarro M, Montanes A. Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses. J Allergy Clin Immunol 2009;124:157161.e1-32.
  • 80
    Casale TB, Canonica GW, Bousquet J, Cox L, Lockey R, Nelson HS et al. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol 2009;124:665670.
  • 81
    Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117:10211035.
  • 82
    Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006;61:12361237.
  • 83
    Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008;63:374.
  • 84
    de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009;64:963964.
  • 85
    Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006;61:1235.
  • 86
    Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007;62:567568.
  • 87
    Mungan D, Misirligil Z, Gürbüz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma-a placebo controlled study. Ann Allergy Asthma Immunol 1999;82:485490.
  • 88
    Quirino T, Lemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996;26:12531261.
  • 89
    Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; Art. No.: CD001186. DOI: 10.1002/14651858. CD001186.pub2.